BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 30694564)

  • 21. HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.
    Laino AS; Betts BC; Veerapathran A; Dolgalev I; Sarnaik A; Quayle SN; Jones SS; Weber JS; Woods DM
    J Immunother Cancer; 2019 Feb; 7(1):33. PubMed ID: 30728070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth.
    Van Helleputte L; Kater M; Cook DP; Eykens C; Rossaert E; Haeck W; Jaspers T; Geens N; Vanden Berghe P; Gysemans C; Mathieu C; Robberecht W; Van Damme P; Cavaletti G; Jarpe M; Van Den Bosch L
    Neurobiol Dis; 2018 Mar; 111():59-69. PubMed ID: 29197621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The HDAC6 Inhibitor Tubacin Induces Release of CD133
    Chao OS; Chang TC; Di Bella MA; Alessandro R; Anzanello F; Rappa G; Goodman OB; Lorico A
    J Cell Biochem; 2017 Dec; 118(12):4414-4424. PubMed ID: 28452069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
    Kassab SE; Mowafy S; Alserw AM; Seliem JA; El-Naggar SM; Omar NN; Awad MM
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.
    Wu H; Yang K; Zhang Z; Leisten ED; Li Z; Xie H; Liu J; Smith KA; Novakova Z; Barinka C; Tang W
    J Med Chem; 2019 Aug; 62(15):7042-7057. PubMed ID: 31271281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.
    Tavares MT; Kozikowski AP; Shen S
    Eur J Med Chem; 2021 Jan; 209():112887. PubMed ID: 33035922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
    Rabal O; Sánchez-Arias JA; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; García-Barroso C; Ugarte A; Estella-Hermoso de Mendoza A; Sáez E; Espelosin M; Ursua S; Haizhong T; Wei W; Musheng X; Garcia-Osta A; Oyarzabal J
    Eur J Med Chem; 2018 Apr; 150():506-524. PubMed ID: 29549837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019).
    He X; Li Z; Zhuo XT; Hui Z; Xie T; Ye XY
    Recent Pat Anticancer Drug Discov; 2020; 15(1):32-48. PubMed ID: 32065106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease.
    Pinho BR; Reis SD; Guedes-Dias P; Leitão-Rocha A; Quintas C; Valentão P; Andrade PB; Santos MM; Oliveira JM
    Pharmacol Res; 2016 Jan; 103():328-39. PubMed ID: 26657418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Involvement of HDAC6 in ischaemia and reperfusion-induced rat retinal injury.
    Yuan H; Li H; Yu P; Fan Q; Zhang X; Huang W; Shen J; Cui Y; Zhou W
    BMC Ophthalmol; 2018 Nov; 18(1):300. PubMed ID: 30453928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of specific HDAC6 inhibitor with anti-metastatic effects in pancreatic cancer cells through virtual screening and biological evaluation.
    Song H; Niu X; Quan J; Li Y; Yuan L; Wang J; Ma C; Ma E
    Bioorg Chem; 2020 Apr; 97():103679. PubMed ID: 32120077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
    Brindisi M; Senger J; Cavella C; Grillo A; Chemi G; Gemma S; Cucinella DM; Lamponi S; Sarno F; Iside C; Nebbioso A; Novellino E; Shaik TB; Romier C; Herp D; Jung M; Butini S; Campiani G; Altucci L; Brogi S
    Eur J Med Chem; 2018 Sep; 157():127-138. PubMed ID: 30092367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and Validation of High-Content Analysis for Screening HDAC6-Selective Inhibitors.
    Nong Y; Hou Y; Pu Y; Li S; Lan Y
    SLAS Discov; 2021 Jun; 26(5):628-641. PubMed ID: 33783263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors.
    Goracci L; Deschamps N; Randazzo GM; Petit C; Dos Santos Passos C; Carrupt PA; Simões-Pires C; Nurisso A
    Sci Rep; 2016 Jul; 6():29086. PubMed ID: 27404291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth.
    Kaliszczak M; Trousil S; Åberg O; Perumal M; Nguyen QD; Aboagye EO
    Br J Cancer; 2013 Feb; 108(2):342-50. PubMed ID: 23322205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Groebke Blackburn Bienaymé-mediated multi-component synthesis of selective HDAC6 inhibitors with anti-inflammatory properties.
    Kraft FB; Enns J; Honin I; Engelhardt J; Schöler A; Smith ST; Meiler J; Schäker-Hübner L; Weindl G; Hansen FK
    Bioorg Chem; 2024 Feb; 143():107072. PubMed ID: 38185013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma.
    Peng X; Yu Z; Surineni G; Deng B; Zhang M; Li C; Sun Z; Pan W; Liu Y; Liu S; Yu B; Chen J
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2201408. PubMed ID: 37096557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo.
    Hsieh YL; Tu HJ; Pan SL; Liou JP; Yang CR
    Biochim Biophys Acta Mol Cell Res; 2019 Jun; 1866(6):992-1003. PubMed ID: 30867138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tubacin, an HDAC6 Selective Inhibitor, Reduces the Replication of the Japanese Encephalitis Virus via the Decrease of Viral RNA Synthesis.
    Lu CY; Chang YC; Hua CH; Chuang C; Huang SH; Kung SH; Hour MJ; Lin CW
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28468311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vitamin K
    Dawood M; Hegazy MF; Elbadawi M; Fleischer E; Klinger A; Bringmann G; Kuntner C; Shan L; Efferth T
    Biochem Pharmacol; 2020 Oct; 180():114176. PubMed ID: 32721508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.